OBJECTIVE: To determine the incidence of @entity12042 and its association with @entity309 ( @entity309 ) in a cohort of all renal biopsies at one referral hospital and to measure the effect of a monthly pulse of @entity786 on renal function and survival in these @entity309 @entity1 . METHOD: All renal biopsies with proven @entity2783 from a single pathology unit linked to a major nephrology referral unit in a university hospital were selected retrospectively and @entity309 @entity1 were identified. We studied 6931 renal biopsies. The effect of treatment with and without pulse @entity786 on renal function and survival was studied in these @entity1 . RESULTS: From March 1977 to February 1999, the incidence of @entity2783 was 2.4 cases/yr. The incidence and prevalence of the association of @entity2783 with @entity309 were 0.68 cases/yr and 0.22% (15/6931) respectively. @entity309 @entity1 treated with @entity786 (n=6) had a lower rate of renal function loss (P=0.013) and a higher median survival (P=0.026) than untreated @entity1 (n=9). During the follow-up period, two out of six treated @entity1 (33%) and all nine untreated @entity1 (100%) died. CONCLUSIONS: @entity2783 is a rare complication of @entity309 and complicates the evaluation of treatment. This retrospective study suggests that treatment with @entity786 is able to reduce the incidence of @entity454 and to increase survival. Prospective studies are needed to clarify this issue.

XXXX associated with @entity309 : a cohort study showing improved survival on treatment with pulse @entity786 .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity12042 :: ('MESH:C538249', 'Disease') :: ['renal AA amyloidosis'] @entity2783 :: ('MESH:D000686', 'Disease') :: ['AA amyloidosis'] @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide'] @entity309 :: ('MESH:D001172', 'Disease') :: ['rheumatoid arthritis', 'RA'] @entity454 :: ('MESH:D007676', 'Disease') :: ['end-stage renal failure']
@entity12042 :: (MESH:C538249,Disease) :: ['Renal type AA amyloidosis']
